mechlorethamine (mustargen) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Mechlorethamine also known as mustine, brand name MUSTARGEN administered intravenously is the prototype anticancer chemotherapeutic drug, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. In 2013 was approved orphan drug Valchlor (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Mechlorethamine belongs to the group of nitrogen mustard alkylating agents. Alkylating agents work by three different mechanisms: attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations all of which achieve the same end result - disruption of DNA function and cell death.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral, Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$47.2887 - $50.6422
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2,2'-dichloro-n-methyldiethylamine | beta,beta'-dichlorodiethyl-n-methylamine | bis(2-chloroethyl)methylamine | bis(beta-chloroethyl)methylamine | chlormethine | hn2 hcl | mechlorethamine | mechlorethamine hcl | mechlorethamine hydrochloride | methylbis(2-chloroethyl)amine | methylbis(beta-chloroethyl)amine | mustargen | mustine | nitrogen mustard | nitrogen mustard n-oxide hcl | n-methyl-bis(2-chloroethyl)amine | n-methyl-bis(beta-chloroethyl)amine | tinefcon | valchlor | β,β'-dichlorodiethyl-n-methylamine

Organizations (50)

Research & Development (48)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (6)


 

Hodgkin Disease (approved 1949)

Leukemia, Lymphocytic, Chronic, B-Cell (approved 1949)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (approved 1949)

Lymphoma, Non-Hodgkin (approved 1949)

Lymphoma, T-Cell, Cutaneous

Mycosis Fungoides (approved 1949)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Brain Neoplasms (Phase 2)

Dermatology (Early Phase 1)

Hodgkin Disease (Phase 2)

Lichen Planus (Phase 2)

Lymphoma (Phase 3)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Mycosis Fungoides (Phase 2)

Psoriasis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial Organizations: 48

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue